No black box warning on record for Kalbitor

As of the latest FDA labeling reviewed, Kalbitor (ECALLANTIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Kalbitor medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients. Administer KALBITOR in a setting equipped to manage anaphylaxis and hereditary angioedema. Given the similarity in hypersensitivity symptoms and acute HAE symptoms, monitor patients closely for hypersensitivity reactions ( 5 ). 5.1 Hypersensitivity Reactions, Including A

No black box warning on record for Kalbitor

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients. Administer KALBITOR in a setting equipped to manage anaphylaxis and hereditary angioedema. Given the similarity in hypersensitivity symptoms and acute HAE symptoms, monitor patients closely for hypersensitivity reactions ( 5 ). 5.1 Hypersensitivity Reactions, Including A

Kalbitor Black Box Warning

No black box warning on record for Kalbitor

Other warnings & precautions

Kalbitor Black Box Warning

No black box warning on record for Kalbitor

Other warnings & precautions